Recent Updates
Recently added Catalysts

LY5625573

Phase 2

C-Reactive Protein | Small molecule | Other |Eli Lilly and Company|Trials Updated: Oct 9, 2026

LY5625573 development status

Highest phase Phase 2 run by Zomagen Biosciences Ltd. (NCT06556173)
Phase scored for LLYPhase 1
Registered trials 2 across 2 sponsors since Aug 2024

LY5625573 target and mechanism

ModalitySmall molecule

Also known as VTX3232

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment96

FDA Designations

No designations recorded

LY5625573 clinical trials

LY5625573 · 1 trial · 1 indication

Phase 1 1
NCT07867340A Study of Single and Multiple Doses of LY5625573 in Healthy Participants, Including Japanese and Chinese Populations, and Participants With Inflammation (High C-Reactive Protein)C-Reactive Protein
NOT YET_RECRUITING96 Analytics
PHASE1NOT YET_RECRUITING
A Study of Single and Multiple Doses of LY5625573 in Healthy Participants, Including Japanese and Chinese Populations, and Participants With Inflammation (High C-Reactive Protein)
C-Reactive Protein
NCT0786734096
Unlock trial analytics

Study Endpoints

Primary Endpoints

Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Baseline up to Follow up (Days 12 and 24)
Number of Participants with One or More Treatment-Emergent Adverse Event(s) (TEAEs) Considered by the Investigator to be Related to Study Drug Administration
Baseline up to Follow up (Days 12 and 24)

Secondary Endpoints

Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY5625573
Baseline up to End of Treatment (Day 17)
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeBASIC_SCIENCE

Treatment Arms

ArmTypeDescription
LY5625573 Part A - Single Dose HealthyEXPERIMENTALSingle dose of LY5625573 administered orally in healthy participants
Placebo Part A - Single Dose HealthyPLACEBO_COMPARATORSingle dose of Placebo administered orally in healthy participants
LY5625573 + Midazolam Part B - Multiple Dose HealthyEXPERIMENTALMultiple-ascending dose (MAD) of LY5625573 and midazolam co-administered orally in healthy participants
Placebo + Midazolam Part B - Multiple Dose HealthyPLACEBO_COMPARATORMultiple doses of Placebo and midazolam co-administered orally in healthy participants
LY5625573 Part C - Multiple Dose Elevated hsCRPEXPERIMENTALMAD of LY5625573 administered orally in participants with elevated high-sensitivity C-reactive protein (hsCRP)
Placebo Part C - Multiple Dose Elevated hsCRPPLACEBO_COMPARATORMultiple doses of Placebo administered orally in participants with elevated hsCRP
LY5625573 Part D - Healthy JapaneseEXPERIMENTALMAD of LY5625573 administered orally in healthy Japanese participants
Placebo Part D - Healthy JapanesePLACEBO_COMPARATORMultiple doses of Placebo administered orally in healthy Japanese participants
LY5625573 Part E - Healthy ChineseEXPERIMENTALMAD of LY5625573 administered orally in healthy Chinese participants
Placebo Part E - Healthy ChinesePLACEBO_COMPARATORMultiple doses of Placebo administered orally in healthy Chinese participants

Interventions

NameTypeDescription
LY5625573DRUGAdministered orally as tablet
MidazolamDRUGAdministered orally
PlaceboDRUGAdministered orally as tablet
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 65 Years
SexALL
Healthy VolunteersYes
Study Sites3

Inclusion Criteria: * 21 to 65 years of age, inclusive, at the time of signing the informed consent if enrolled in Singapore * Are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, vital signs, and cardiac monitoring * Have clinic...

Countries:United StatesSingapore
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWOct 9, 2026NCT07867340NEW_TRIAL: changed
LOWOct 9, 2026NCT07867340NEW_TRIAL: changed

Explore more on BiopharmaWatch

Eli Lilly and Company (LLY)Pipeline, catalysts, financials, insiders and newsBiotech disease mapWho is developing what in each indication, and how crowded it isFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with LCompanies A to ZEvery biotech and pharma company we track